The systemic vasculitides are multisystem disorders with considerable mortality and morbidity and frequent relapses. In the absence of reliable serological markers, accurate clinical tools are required to assess disease activity and damage for treatment decisions, and for the performance of clinical trials. This article reviews and summarises the development and use of disease assessment tools for determining activity and damage in systemic vasculitis and reports ongoing initiatives for further development of disease assessment tools. A literature search was conducted using PubMed and reference lists for vasculitis, assessment, clinical trials, outcome and prognosis. The findings indicate that comprehensive disease assessment in vasculitis requires documentation of disease activity, chronic irreversible damage and impairment of function.
- ANCA, antineutrophil cytoplasmic antibody
- BVAS, Birmingham Vasculitis Activity Score
- BVAS/WG, Birmingham Vasculitis Activity Score for Wegener’s granulomatosis
- DEI, Disease Extent Index
- EUVAS, European Vasculitis Study Group
- FFS, Five Factor Score
- ITU, intensive treatment unit
- OMERACT, Outcome Measures for Arthritis Clinical Trials
- VDI, Vasculitis Damage Index
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.